SGLT2 inhibitors may reduce resting BP and skeletal muscle reflexes independent of glycemic control
Dallas, TX: Recent data have shown a novel role for SGLT2 inhibitors independent of glycemic control, in reducing resting blood pressure (BP) and activity of skeletal muscle reflexes. The findings of the study, published in the journal Hypertension, may be important for the prevention of hypertension and hypertensive heart disease in young prehypertensive patients.
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are a class of anti-diabetic medications that have been shown to reduce BP in hypertensive type 2 diabetes patients. There is no clarity on the mechanism of action underlying this but SGLT2i-induced sympathoinhibition is suggested to play a role. Wanpen Vongpatanasin, University of Texas Southwestern Medical Center, Dallas, TX, and colleagues aimed to determine whether SGLT2i reduces BP and sympathetic nerve activity (SNA) in a nondiabetic prehypertension model.
For this purpose, the researchers assessed changes in conscious BP using radiotelemetry and alterations in mean arterial pressure and renal SNA. This was done during simulated exercise in nondiabetic spontaneously hypertensive rats during chronic administration of a diet containing dapagliflozin (0.5 mg/kg per day) versus a control diet.
Key findings of the study include:
· Dapagliflozin was found to have no effect on fasting blood glucose, insulin, or hemoglobin A1C levels.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.